Background-A number of instruments have been developed for determination of prothrombin time (PT) and International Normalised Ratio (INR) at locations not limited to central laboratories. Aim-To evaluate one such portable instrument, the Thrombolytic Assessment System (TAS), which can be used in a near-patient setting. Methods-Samples from 20 normal subjects and 48 patients treated with warfarin for venous thromboembolic disease were studied. The warfarin group was divided into: initiation phase (n = 10), combined warfarin and heparin (n = 10), stabilised therapy (n = 20), and over anticoagulated patients (n = 8). PTs and INRs were determined in each group using three conventional thromboplastins (Diagen Activated, Manchester Reagent, and Instrumentation Laboratory) and two TAS techniques (whole blood or plasma). An independent International Sensitivity Index (ISI) calibration of the TAS system was performed. Results (7 Clin Pathol 1997;50:951-956) 
Oral anticoagulants are widely used for the prevention and treatment of thromboembolic disease.' Optimal oral anticoagulant dosage regimens reflect a balance between the antithrombotic effects of these drugs and unwanted haemorrhagic side effects. Warfarin dose adjustments necessitate reliable laboratory monitoring. The test most commonly used for this purpose is the prothrombin time (PT) expressed as International Normalised Ratio (INR). The INR system is a standardised system of reporting that takes account of the variability in the responsiveness of thromboplastins to the defect induced by coumarin drugs.2' The theoretical advantage of this system is that the same INR is obtained irrespective of the laboratory reagent used, and its introduction has undoubtedly contributed to improvement in the laboratory control of oral anticoagulant treatment. 4 The problems of large scale laboratory monitoring of oral anticoagulants particularly in an outpatient setting, have led to the recent development of a number of near-patient testing instruments. 5`10 One such portable instrument is the Thrombolytic Assessment System (TAS) that can be used to determine PT and INR in a nearpatient setting.7 We compared INR results obtained with this instrument to those obtained using three thromboplastins in common use in the UK.
Materials and methods

SAMPLES
Venous blood samples were collected in the proportion 9 parts blood to 1 part 0.105 M buffered trisodium citrate (Vacutainer, BectonDickinson Ltd, Cowley, Oxford, UK). One millilitre of whole blood was transferred to a stoppered plastic container and the remaining 4 ml centrifuged at 2000 xg for 10 minutes at room temperature. The citrated whole blood sample was tested using the TAS system only, whereas the citrated platelet poor plasma was tested using the TAS system and three conventional thromboplastins. 
DETERMINATION OF INR: TAS INSTRUMENT
Single test PT and INRs were determined using both plasma and whole blood samples for each patient. The analyser and test cards were used according to manufacturer's instructions. A measured volume of 35 ,ul (whole blood or plasma) was used except where stated. The applied blood sample dissolves the dried human placental thromboplastin/calcium contained within the card. For the card batch used the following values had been encoded by the manufacturer: plasma, MNPT 10.9 seconds and ISI 0.98; whole blood, MNPT 11.4 seconds and ISI 0.97.
INR values for the TAS system were those calculated and automatically displayed by the TAS instrument (that is, using the manufacturer's MNPT and ISI) unless otherwise stated. For INRs > 5 as determined by the TAS system, only PT and PT ratios were displayed. In these cases the INR was calculated using the appropriate ISI and formula INR = PT ratio's'.
The importance of volume of applied blood drop on INR as determined using the TAS system was assessed. Whole blood samples from 10 patients on warfarin were analysed twice, first using a measured 35 gl volume of whole blood, and second using an unmeasured droplet of unknown volume applied using a disposable plastic Pasteur pipette. The order of testing with the two methods was varied.
Use of a local mean normal prothrombin time Two INRs were calculated for each patient's whole blood PT determined using the TAS instrument. The first was derived from the manufacturer's values for ISI and MNPT, encoded in the test cards. The second was calculated using a locally determined MNPT (geometric mean PT of 20 fresh normal samples).
pies on the TAS system. In each case the coefficient of variation (CV) was calculated (standard deviation/mean x 100%) as an indication of precision.
-------+2-SD = -0.89------ warfarinised patients when samples were analysed as whole blood and as plasma after centrifugation. Either sample type could therefore be used in routine practice.
The main principle of the INR system is that the same result should be obtained irrespective of the reagent used for INR determinations. Differences between INRs determined using different conventional thromboplastins have been reported. '9 20 In the present study INRs determined on whole blood using the TAS instrument and manufacturer's MNPT were less than results obtained with DA and IL reagents. These differences were sufficient (11-16%) to influence patient management in some cases and were similar in magnitude to differences present when two conventional reagents (MR and IL) included in the study were compared. These differences were greater at greater INRs. In contrast, results obtained on plasma samples (rather than whole blood) using the TAS analyser were similar to those obtained with conventional thromboplastins. Both ISI and MNPT values are encoded into test cards by the manufacturer. In the present study the TAS ISI values were assessed according to WHO recommended criteria'2 and with the reference thromboplastin BCT-44 1.13 Calculated ISIs for plasma and whole blood were 4.8% and 1.4% greater than manufacturer's stated values, respectively. This essentially confirms the manufacturer's values, particularly for whole blood and therefore does not explain the difference in INR values between TAS whole blood and conventional thromboplastins. In the present study, the locally determined MNPT for whole blood samples was 10.6 seconds compared to the manufacturer's value of 11.4 seconds. Use of the local MNPT increased INRs determined with the TAS and improved agreement with conventional reagents. The statistically significant differences between TAS results (whole blood; all patient groups combined) and either DA or IL were abolished. Within the subgroup of stabilised patients, TAS (whole blood) results did however remain significantly lower than results obtained with IL. This difference (13%) was practically identical to that observed between MR and IL in this group. We have confirmed the manufacturer's ISI for TAS (whole blood) but the possibility that inaccurate assignment of ISI to conventional thromboplastins has contributed to the differences described cannot be excluded from our data.
We have demonstrated that the TAS system can be used for determination of INR using plasma or whole blood with the manufacturer's ISI. Agreement with INRs determined using conventional thromboplastins was improved by the use of a locally determined MNPT in our study, suggesting that this approach should be adopted where possible. Differences between INRs obtained with TAS and one commonly used UK conventional thromboplastin were present in a group of patients within the therapeutic range for INR but were similar to the difference between this and another conventional thromboplastin.
